Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis

Background. In-stent restenosis (ISR) remains a common problem following percutaneous coronary intervention (PCI). However, the best treatment strategy remains uncertain. There is some controversy over the efficacy of drug-eluting balloons (DEBs) and second-generation drug-eluting stents (DESs) for...

Full description

Saved in:
Bibliographic Details
Main Authors: Wen-Juan Xiu, Hai-Tao Yang, Ying-Ying Zheng, Yi-Tong Ma, Xiang Xie
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2018/7658145
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849473267273826304
author Wen-Juan Xiu
Hai-Tao Yang
Ying-Ying Zheng
Yi-Tong Ma
Xiang Xie
author_facet Wen-Juan Xiu
Hai-Tao Yang
Ying-Ying Zheng
Yi-Tong Ma
Xiang Xie
author_sort Wen-Juan Xiu
collection DOAJ
description Background. In-stent restenosis (ISR) remains a common problem following percutaneous coronary intervention (PCI). However, the best treatment strategy remains uncertain. There is some controversy over the efficacy of drug-eluting balloons (DEBs) and second-generation drug-eluting stents (DESs) for treating ISR. Methods. A meta-analysis was used to compare the efficacy of the DEB and second-generation DES in the treatment of ISR. The primary endpoint is the incidence of target lesion revascularization (TLR). The secondary endpoint is the occurrence of target vessel revascularization (TVR), myocardial infarction (MI), all-cause death (ACM), cardiac death (CD), major adverse cardiac events (MACEs), minimum luminal diameter (MLD), late luminal loss (LLL), binary restenosis (BR), and percent diameter stenosis (DS%). Results. A total of 12 studies (4 randomized controlled trials and 8 observational studies) including 2020 patients with a follow-up of 6–25 months were included in the present study. There was a significant difference in the MLD between the two groups during follow-up (P=0.007, RR = 0.23, and 95% CI: 0.06–0.4 mm). There was no significant difference in LLL, BR, or DS% and the overall incidence of MACEs between the two groups. Subgroup analysis showed no significant difference in the incidence of primary and secondary endpoints when considering RCTs or observational studies only. Conclusions. The efficacy of the DEB and second-generation DES in the treatment of ISR is comparable. However, our results need further verification through multicenter randomized controlled trials.
format Article
id doaj-art-d338b10175f445a7b51be961067dac30
institution Kabale University
issn 2090-8016
2090-0597
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-d338b10175f445a7b51be961067dac302025-08-20T03:24:12ZengWileyCardiology Research and Practice2090-80162090-05972018-01-01201810.1155/2018/76581457658145Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-AnalysisWen-Juan Xiu0Hai-Tao Yang1Ying-Ying Zheng2Yi-Tong Ma3Xiang Xie4Heart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, ChinaHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, ChinaHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, ChinaHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, ChinaHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, ChinaBackground. In-stent restenosis (ISR) remains a common problem following percutaneous coronary intervention (PCI). However, the best treatment strategy remains uncertain. There is some controversy over the efficacy of drug-eluting balloons (DEBs) and second-generation drug-eluting stents (DESs) for treating ISR. Methods. A meta-analysis was used to compare the efficacy of the DEB and second-generation DES in the treatment of ISR. The primary endpoint is the incidence of target lesion revascularization (TLR). The secondary endpoint is the occurrence of target vessel revascularization (TVR), myocardial infarction (MI), all-cause death (ACM), cardiac death (CD), major adverse cardiac events (MACEs), minimum luminal diameter (MLD), late luminal loss (LLL), binary restenosis (BR), and percent diameter stenosis (DS%). Results. A total of 12 studies (4 randomized controlled trials and 8 observational studies) including 2020 patients with a follow-up of 6–25 months were included in the present study. There was a significant difference in the MLD between the two groups during follow-up (P=0.007, RR = 0.23, and 95% CI: 0.06–0.4 mm). There was no significant difference in LLL, BR, or DS% and the overall incidence of MACEs between the two groups. Subgroup analysis showed no significant difference in the incidence of primary and secondary endpoints when considering RCTs or observational studies only. Conclusions. The efficacy of the DEB and second-generation DES in the treatment of ISR is comparable. However, our results need further verification through multicenter randomized controlled trials.http://dx.doi.org/10.1155/2018/7658145
spellingShingle Wen-Juan Xiu
Hai-Tao Yang
Ying-Ying Zheng
Yi-Tong Ma
Xiang Xie
Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
Cardiology Research and Practice
title Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
title_full Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
title_fullStr Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
title_full_unstemmed Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
title_short Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
title_sort drug eluting balloons versus second generation drug eluting stents for treating in stent restenosis in coronary heart disease after pci a meta analysis
url http://dx.doi.org/10.1155/2018/7658145
work_keys_str_mv AT wenjuanxiu drugelutingballoonsversussecondgenerationdrugelutingstentsfortreatinginstentrestenosisincoronaryheartdiseaseafterpciametaanalysis
AT haitaoyang drugelutingballoonsversussecondgenerationdrugelutingstentsfortreatinginstentrestenosisincoronaryheartdiseaseafterpciametaanalysis
AT yingyingzheng drugelutingballoonsversussecondgenerationdrugelutingstentsfortreatinginstentrestenosisincoronaryheartdiseaseafterpciametaanalysis
AT yitongma drugelutingballoonsversussecondgenerationdrugelutingstentsfortreatinginstentrestenosisincoronaryheartdiseaseafterpciametaanalysis
AT xiangxie drugelutingballoonsversussecondgenerationdrugelutingstentsfortreatinginstentrestenosisincoronaryheartdiseaseafterpciametaanalysis